|
1.
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011.
|
|
2.
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007.
|
|
3.
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA,
Parmiani G, Castelli C and Clarke MF: Phenotypic characterization
of human colorectal cancer stem cells. Proc Natl Acad Sci USA.
104:10158–10163. 2007.
|
|
4.
|
Monzani E, Facchetti F, Galmozzi E,
Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D,
Santinami M, Invernici G, Parati E, Alessandri G and La Porta CA:
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. Eur J Cancer. 43:935–946. 2007.
|
|
5.
|
Immervoll H, Hoem D, Sakariassen PØ,
Steffensen OJ and Molven A: Expression of the ‘stem cell marker’
CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC
Cancer. 8:482008.
|
|
6.
|
Marhaba R, Klingbeil P, Nuebel T,
Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM:
cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008.
|
|
7.
|
Wu Y and Wu PY: CD133 as a marker for
cancer stem cells: progresses and concerns. Stem Cells Dev.
18:1127–1134. 2009.
|
|
8.
|
An Y and Ongkeko WM: ABCG2: the key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009.
|
|
9.
|
Lathia JD, Gallagher J, Heddleston JM,
Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE,
Hjelmeland AB and Rich JN: Integrin alpha 6 regulates glioblastoma
stem cells. Cell Stem Cell. 6:421–432. 2010.
|
|
10.
|
Yin AH, Miraglia S, Zanjani ED,
Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck
DW: AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood. 90:5002–5012. 1997.
|
|
11.
|
Guzmán-Ramírez N, Völler M, Wetterwald A,
Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN and
Cecchini MG: In vitro propagation and characterization of
neoplastic stem/progenitor-like cells from human prostate cancer
tissue. Prostate. 69:1683–1693. 2009.
|
|
12.
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
|
|
13.
|
Ueki H, Watanabe M, Kaku H, Huang P, Li
SA, Ochiai K, Hirata T, Noguchi H, Yamada H, Takei K, Nasu Y,
Kashiwakura Y and Kumon H: A novel gene expression system for
detecting viable bladder cancer cells. Int J Oncol. 41:135–140.
2012.
|
|
14.
|
Hirata T, Watanabe M, Kaku H, Kobayashi Y,
Yamada H, Sakaguchi M, Takei K, Huh NH, Nasu Y and Kumon H: REIC/
Dkk-3 encoding adenoviral vector as a potentially effective
therapeutic agent for bladder cancer. Int J Oncol. 41:559–564.
2012.
|
|
15.
|
Watanabe M, Ueki H, Ochiai K, Huang P,
Kobayashi Y, Nasu Y, Sasaki K, Kaku H, Kashiwakura Y and Kumon H:
Advanced two-step transcriptional amplification as a novel method
for cancer-specific gene expression and imaging. Oncol Rep.
26:769–775. 2011.
|
|
16.
|
Bidlingmaier S, Zhu X and Liu B: The
utility and limitations of glycosylated human CD133 epitopes in
defining cancer stem cells. J Mol Med (Berl). 86:1025–1032.
2008.
|
|
17.
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005.
|
|
18.
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008.
|
|
19.
|
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK,
Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH and Chiou SH:
Oct-4 expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PloS One. 3:e26372008.
|
|
20.
|
Walter D, Satheesha S, Albrecht P,
Bornhauser BC, D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I,
Koscielniak E, Gengler C, Moch H, Bernasconi M, Niggli FK and
Schäfer BW; CWS Study Group: CD133 positive embryonal
rhabdomyosarcoma stem-like cell population is enriched in
rhabdospheres. PloS One. 6:e195062011.
|
|
21.
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
|
|
22.
|
Marques DS, Sandrini JZ, Boyle RT, Marins
LF and Trindade GS: Relationships between multidrug resistance
(MDR) and stem cell markers in human chronic myeloid leukemia cell
lines. Leuk Res. 34:757–762. 2010.
|
|
23.
|
Chiou SH, Kao CL, Chen YW, Chien CS, Hung
SC, Lo JF, Chen YJ, Ku HH, Hsu MT and Wong TT: Identification of
CD133-positive radioresistant cells in atypical teratoid/rhabdoid
tumor. PloS One. 3:e20902008.
|
|
24.
|
Blazek ER, Foutch JL and Maki G: Daoy
medulloblastoma cells that express CD133 are radioresistant
relative to CD133− cells, and the CD133+
sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys.
67:1–5. 2007.
|
|
25.
|
Fong YW, Inouye C, Yamaguchi T, Cattoglio
C, Grubisic I and Tjian R: A DNA repair complex functions as an
Oct4/Sox2 coactivator in embryonic stem cells. Cell. 147:120–131.
2011.
|
